Sign in

SXTC on Nasdaq

China SXT Pharmaceuticals, Inc.

China SXT Pharmaceuticals, Inc. is a pharmaceutical preparations company based in Road Town, British Virgin Islands.2 Its shares trade on Nasdaq under the symbol SXTC.2

Price unavailable

Last updated Oct 21, 2026.

Overview

$1.1MRevenue, fiscal 20263
-$6.2MNet income, fiscal 20263

Compare with Bespoke Extracts, Inc., Neuphoria Therapeutics Inc. or Bioline Rx Ltd., or pick any stock.

  • TickerSXTC on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersRoad Town, British Virgin Islands2
  • Incorporated inVirgin Islands, British4
  • Business address178 Taidong Road North, Taizhou4
  • Filer categoryNon-accelerated filer4
  • Legal formcompany limited by shares2
  • LEI5493006HSPECSOT1UH872
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o Vistra (BVI) Limited Vistra Corporate Services Centre Wickhams Cay II, VG1110 Road Town, British Virgin Islands2
  • Registered withRegistry of Corporate Affairs (British Virgin Islands Financial Services Commission), 19496642

See how the biggest companies compare on our leaderboards

As such, WFOE’s business scope is to primarily engage in technology development, provision of technology service, technology consulting;5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

21.9%Gross margin3
-625.9%Operating margin3
-545.2%Net margin3
-34.6%Revenue growth, 20263
-20.9%Return on equity3
0.02×Debt to equity3

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Regular TCMP brought in 95% of the revenue China SXT Pharmaceuticals, Inc. broke down this way in fiscal 2026.

  1. Regular TCMP$1.1M395%down 25% from 2025
  2. Advanced TCMP$49.5K34%down 81% from 2025
  3. Others$7.1K31%down 82% from 2025
  4. Revenue From Related Parties$4130%down 99% from 2025
Products and services by year
Products and services202420252026
Regular TCMP$1.4M$1.1M
Advanced TCMP$258.4K$49.5K
Others$40.0K$7.1K
Revenue From Related Parties$27.8K$4.3K$41

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue78¢$889.4K
  • Other costs22¢$248.7K

Out of $1.1M in revenue.3 The company lost money this year.

Financial statements

Revenue67893$1.1M in 2026−84% since 2019
0$2.0M$4.0M$6.0M$8.0M2019: $7.0M$7.0M20192020: $5.2M$5.2M2020−26%2021: $4.8M$4.8M2021−7%2022: $2.6M$2.6M2022−46%2023: $2.0M$2.0M2023−24%2024: $1.9M$1.9M2024−2%2025: $1.7M$1.7M2025−10%2026: $1.1M$1.1M2026−35%
Gross profit6789103$248.7K in 2026−95% since 2019
0$2.0M$4.0M$6.0M2019: $4.6M$4.6M20192020: $2.7M$2.7M2020−41%2021: $2.8M$2.8M2021+5%2022: $1.3M$1.3M2022−56%2023: $426.3K$426.3K2023−66%2024: $554.0K$554.0K2024+30%2025: $367.4K$367.4K2025−34%2026: $248.7K$248.7K2026−32%
Operating income6789103-$7.1M in 2026
-$7.5M-$5.0M-$2.5M0$2.5M2019: $1.8M$1.8M20192020: -$1.3M-$1.3M20202021: -$2.2M-$2.2M2021+64%2022: -$5.2M-$5.2M2022+136%2023: -$5.6M-$5.6M2023+8%2024: -$2.5M-$2.5M2024−55%2025: -$2.7M-$2.7M2025+7%2026: -$7.1M-$7.1M2026+166%
Net income6789103-$6.2M in 2026
-$15.0M-$10.0M-$5.0M0$5.0M2019: $1.5M$1.5M20192020: -$10.3M-$10.3M20202021: -$2.7M-$2.7M2021−73%2022: -$5.7M-$5.7M2022+109%2023: -$5.9M-$5.9M2023+3%2024: -$3.1M-$3.1M2024−48%2025: -$3.3M-$3.3M2025+7%2026: -$6.2M-$6.2M2026+88%

Every line of the income statement as filed: the last 3 fiscal years, latest first.3

Period ending2026-03-312025-03-312024-03-31
Revenues$1.1M$1.7M$1.9M
Cost of revenues-$889.4K-$1.4M-$1.4M
Gross profit$248.7K$367.4K$554.0K
Selling and marketing-$244.2K-$289.9K-$433.6K
General and administrative-$7.1M-$2.8M-$2.6M
Total operating expenses-$7.4M-$3.0M-$3.1M
Operating loss-$7.1M-$2.7M-$2.5M
Interest expenses, net-$63.0K-$648.2K-$544.3K
Other income (expenses), net$980.8K$25.0K-$39.0K
Total other income (expenses), net$917.8K-$623.2K-$583.3K
Loss before income taxes-$6.2M-$3.3M-$3.1M
Net loss-$6.2M-$3.3M-$3.1M
Foreign currency translation income (loss)$877.6K-$49.7K-$828.2K
Comprehensive loss-$5.3M-$3.4M-$3.9M
Basic (in Dollars per share)-$9.13-$348.17-$4,285.66
Diluted (in Dollars per share)-$9.13-$348.17-$4,285.66
Basic (in Shares)679.6K shares9.5K shares723 shares
Diluted (in Shares)679.6K shares9.5K shares723 shares

Compare China SXT Pharmaceuticals, Inc. with another company

Corporate structure

China SXT Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of China SXT Pharmaceuticals, Inc.

  • Orca Capital AG Filed SCHEDULE 13G on China SXT Pharmaceuticals, Inc., latest Oct 15, 2026
  • Cheng Guan Tan Filed SCHEDULE 13G on China SXT Pharmaceuticals, Inc., latest Aug 7, 2025
  • Choon Hwa Ching Filed SCHEDULE 13G on China SXT Pharmaceuticals, Inc., latest Aug 7, 2025
  • Soo Seng Tan Filed SCHEDULE 13G on China SXT Pharmaceuticals, Inc., latest Aug 7, 2025
  • Soon Hong Randy Foong Filed SCHEDULE 13G on China SXT Pharmaceuticals, Inc., latest Aug 7, 2025
  • Streeterville Capital LLC Filed SCHEDULE 13G/A on China SXT Pharmaceuticals, Inc., latest Jan 21, 2025 (5 filings since Aug 25, 2022)
  • Forsakringsaktiebolaget Avanza Pension Filed SC 13G/A on China SXT Pharmaceuticals, Inc., latest Aug 15, 2024 (4 filings since Feb 9, 2024)
  • Lind Global Fund II LP Filed SC 13G/A on China SXT Pharmaceuticals, Inc., latest Feb 13, 2023 (2 filings since Jan 21, 2022)
  • Albert Feng Zhou Filed SC 13D/A on China SXT Pharmaceuticals, Inc., latest Jan 30, 2023
  • China SXT Pharmaceuticals, Inc. Road Town, British Virgin Islands

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What China SXT Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$2.7M3 Mar 31, 2026$2.6M3 Mar 31, 2025+5.2%
Accumulated depreciation$2.2M3 Mar 31, 2026$2.0M3 Mar 31, 2025+8.7%
Property and equipment, net$117.1K3 Mar 31, 2026$178.6K3 Mar 31, 2025−34.4%
Operating-lease assets (leased space)$121.4K3 Mar 31, 2026$176.6K3 Mar 31, 2025−31.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$28.2M3 Mar 31, 2026$18.1M3 Mar 31, 2025+55.7%
Deposits held (banks)$7.3M10 Mar 31, 2025

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$6.3K3 Mar 31, 2026$11.8K3 Mar 31, 2025−46.4%
Finite-lived intangibles, gross$78.8K3 Mar 31, 2026$74.9K3 Mar 31, 2025+5.2%
Accumulated amortization$72.5K3 Mar 31, 2026$63.1K3 Mar 31, 2025+14.9%
Finite-lived intangibles, net$6.3K3 Mar 31, 2026$11.8K3 Mar 31, 2025−46.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$777.1K3 Mar 31, 2026$828.1K3 Mar 31, 2025−6.2%
Raw materials$277.0K3 Mar 31, 2026$435.8K3 Mar 31, 2025−36.4%
Finished goods$639.6K3 Mar 31, 2026$448.7K3 Mar 31, 2025+42.6%

Leadership

Who has led China SXT Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Lim Sze Beng Simon2026–now

Chief financial officer

  1. Xiaodong Sean Pan2026–now
Board members and other officers (3)

Timeline

  1. Apr 27, 2026New chief executive Lim Sze Beng Simon becomes CEO12
  2. Jul 4, 2017Founded China SXT Pharmaceuticals, Inc. is founded2

Filings

94 filings to the SEC since October 2021: 6 annual reports, 7 insider forms, 17 large holders, 64 other. The latest 20:

  1. Oct 15, 2026SCHEDULE 13G EDGAR
  2. Oct 9, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  3. Oct 9, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
  4. Oct 8, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  5. Oct 8, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  6. Sep 16, 2026EFFECT EDGAR
  7. Aug 28, 2026F-3/A AMENDMENT NO. 1 TO FORM F-3 EDGAR
  8. Aug 28, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  9. Jul 24, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  10. Jul 24, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
  11. Jul 7, 2026F-3 REGISTRATION STATEMENT EDGAR
  12. Jul 6, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  13. Jul 1, 202620-F ANNUAL REPORT EDGAR
  14. Jun 1, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  15. Jun 1, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
  16. May 4, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  17. Apr 27, 20263 EDGAR
  18. Apr 27, 20263 EDGAR
  19. Apr 27, 20263 EDGAR
  20. Apr 27, 20263 EDGAR

The 94 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Orca Capital AGSCHEDULE 13G, 1 filing Oct 15, 202617
  • Cheng Guan TanSCHEDULE 13G, 1 filing Aug 7, 202518
  • Choon Hwa ChingSCHEDULE 13G, 1 filing Aug 7, 202519
  • Soo Seng TanSCHEDULE 13G, 1 filing Aug 7, 202520
  • Soon Hong Randy FoongSCHEDULE 13G, 1 filing Aug 7, 202521
  • Streeterville Capital LLCSCHEDULE 13G/A, 5 filings Aug 25, 2022 to Jan 21, 202522
  • Avanza Pension ForsakringsaktiebolagetSC 13G/A, 4 filings Feb 9, 2024 to Aug 15, 202423
  • Lind Global Fund II LPSC 13G/A, 2 filings Jan 21, 2022 to Feb 13, 202324
  • Albert Feng ZhouSC 13D/A, 1 filing Jan 30, 202325

SEC filer profile

How China SXT Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARChina SXT Pharmaceuticals, Inc.1
  • CIK0001723980
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company5
  • Incorporated inBritish Virgin Islands5
  • Fiscal year endsMarch 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address178 Taidong Road North, Taizhou, China1
  • Phone86523862982901
  • Shares outstanding958,077 shares as of Mar 31, 20265
  • AuditorEnrome LLP, Singapore PCAOB ID 6907; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceDec 4, 20171
  • Filings168 in all: 6-K (55), CORRESP (13), UPLOAD (11), 424B5 (10), SC 13G/A (9), 20-F (8), F-1/A (8), 3 (7)1
    All 29 form types

    EFFECT (6), SC 13G (6), SCHEDULE 13G (5), F-3 (4), S-8 (4), NT 20-F (3), 20-F/A (2), 424B3 (2), F-1 (2), FWP (2), 424B4 (1), 424B7 (1), 424B8 (1), 6-K/A (1), 8-A12B (1), CERT (1), F-3/A (1), POS AM (1), SC 13D (1), SC 13D/A (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (20-F) Jul 1, 2026

Securities registered for trading

ClassSymbolExchange
Class A Ordinary shares, no par value eachNASDAQ

From the cover page of the 20-F filed Jul 1, 2026 (Section 12(b) of the Exchange Act).5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25